Publications by authors named "Chongyang Deng"

Claim this Profile
P
Pharmacokinetics and Drug-Drug Interaction of Allisartan Isoproxil and Indapamide Sustained-Release Formulation.
Wu Yi, Sisi Lin, Rui Hao, Yiming Shao, Yannan Wang, Chongyang Deng

Clin Pharmacol Drug Dev· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics and Safety of a Single Dose and Multiple Doses of Allisartan Isoproxil, an Angiotensin II Receptor Blocker, in Healthy Chinese People.
Wu Yi, Peiyuan Yan, Sisi Lin, Rui Hao, Yannan Wang, Chongyang Deng

Clin Pharmacol Drug Dev· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of a Potent, Selective Renal Sodium-Dependent Glucose Cotransporter 2 (SGLT2) Inhibitor (HSK0935) for the Treatment of Type 2 Diabetes.
Yao Li, Zongjun Shi, Lei Chen, Suxin Zheng, Sheng Li, Chongyang Deng

J Med Chem· May 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rational design, synthesis, and pharmacological properties of pyranochalcone derivatives as potent anti-inflammatory agents.
Fei Peng, Guangcheng Wang, Xiuxia Li, Dong Cao, Zhuang Yang, Chongyang Deng

Eur J Med Chem· August 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Synthesis and evaluation of 5-benzylidenethiazolidine-2,4-dione derivatives for the treatment of non-alcoholic fatty liver disease.
Liang Ma, Jinying Chen, Xiaolin Liang, Caifei Xie, Chongyang Deng

Arch Pharm (Weinheim)· July 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
(
(Z)2-(5-(4-methoxybenzylidene)-2, 4-dioxothiazolidin-3-yl) acetic acid protects rats from CCl(4) -induced liver injury.
Zhen-ling Wang, Chong-yang Deng, Hao Zheng, Cai-feng Xie, Xian-huo Wang

J Gastroenterol Hepatol· May 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A novel small molecule, (E)-5-(2,4-di-tert-butyl-6-((2,4-dioxothiazolidin-5-ylidene)methyl)phenyl)-5'-methyl-7,7'-dimethoxy-4,4'-bibenzo[d][1,3]dioxole-5,5'-dicarboxylate (7k), alleviates the development of D-galactosamine/lipopolysaccharide-induced acute liver failure by inhibiting macrophage infiltration and regulating cytokine expression.
Chongyang Deng, Juan Liu, Guangcheng Wang, Liang Ma, Caifeng Xie

J Pharmacol Exp Ther· April 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
(
(Z)-5-(4-methoxybenzylidene)thiazolidine-2,4-dione protects rats from carbon tetrachloride-induced liver injury and fibrogenesis.
Zhi-Zhi Chen, Zheng-Lin Wang, Chong-Yang Deng, Hao Zheng, Xian-Huo Wang

World J Gastroenterol· February 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Synthesis and biological evaluation of novel dimethyl[1,1'-biphenyl]-2,2'-dicarboxylate derivatives containing thiazolidine-2,4-dione for the treatment of concanavalin A-induced acute liver injury of BALB/c mice.
Guangcheng Wang, Chongyang Deng, Caifeng Xie, Liang Ma, Jincheng Yang

Eur J Med Chem· December 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preparation, characterization, pharmacokinetics, and bioactivity of honokiol-in-hydroxypropyl-β-cyclodextrin-in-liposome.
Xianhuo Wang, Linyu Deng, Lulu Cai, Xiaoyan Zhang, Hao Zheng, Chongyang Deng

J Pharm Sci· August 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A novel agonist of PPAR-γ based on barbituric acid alleviates the development of non-alcoholic fatty liver disease by regulating adipocytokine expression and preventing insulin resistance.
Hao Zheng, Shilin Li, Liang Ma, Ling Cheng, Chongyang Deng

Eur J Pharmacol· June 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Improved solubility and pharmacokinetics of PEGylated liposomal honokiol and human plasma protein binding ability of honokiol.
Xian-Huo Wang, Lu-Lu Cai, Xiao-Yan Zhang, Lin-Yu Deng, Hao Zheng, Chong-Yang Deng

Int J Pharm· May 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Honokiol crosses BBB and BCSFB, and inhibits brain tumor growth in rat 9L intracerebral gliosarcoma model and human U251 xenograft glioma model.
Xianhuo Wang, Xingmei Duan, Guangli Yang, Xiaoyan Zhang, Linyu Deng, Chongyang Deng

PLoS One· April 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis